BGMA: More than 50% of UK generics face shortages without licensed alternatives

A recent report by the British Generic Manufacturers Association (BGMA) has shed light on ongoing supply challenges in England’s generic medicines market,
revealing significant issues impacting patient care.

The report highlights significant challenges faced in supply of medicines as currently, 51.72 per cent of generics in short supply lack licensed alternatives,
posing substantial hurdles to ensuring continuous patient care.

Additionally, 39.08 per cent of affected generics are branded, indicating widespread disruptions across the market.

A notable 26.44 per cent of generics experiencing shortages have been affected for over six months, highlighting persistent difficulties in supply chain management.

The report indicates that 0.15 per cent of generic medicine presentations listed in the Drug Tariff are currently facing supply issues, impacting accessibility